Table 4.
Multivariate Analysis of Factors Related to DFS and OS in GC Patients
| GC patients |
77 cases |
57 cases who received platinum-based adjuvant chemotherapy |
||||||
|---|---|---|---|---|---|---|---|---|
| Variable | DFS |
OS |
DFS |
OS |
||||
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
| BRF1 expression high versus low | 1.997 (1.109–3.598) | 0.021 | 1.741 (0.968–3.133) | 0.064 | – | – | – | – |
| BRCA1 expression high versus low + negative | 1.921 (0.971–3.799) | 0.061 | 2.409 (1.299–4.467) | 0.005 | 2.063 (0.963–4.423) | 0.063 | 2.237 (0.998–5.017) | 0.051 |
| BRCA2 expression high versus low + negative | 3.450 (1.731–6.877) | <0.001 | 3.269 (1.730–6.177) | <0.001 | 4.446 (2.047–9.657) | <0.001 | 6.090 (2.601–14.255) | <0.001 |
| MPO + cell infiltration presence versus absence | 2.028 (1.037–3.964) | 0.039 | 1.153 (0.612–2.174) | 0.659 | 2.009 (1.000–4.035) | 0.050 | 1.432 (0.705–2.908) | 0.320 |
–, no correlation; HR, homologous recombination.